Umlobi: Clyde Lopez
Usuku Lokudalwa: 24 Ujulayi 2021
Ukuvuselela Usuku: 1 Epreli 2025
Anonim
Niacin (feat. Billy Sheehan) - I Miss You (Like I Miss The Sun) (Live In Tokyo 2005)
Ividiyo: Niacin (feat. Billy Sheehan) - I Miss You (Like I Miss The Sun) (Live In Tokyo 2005)

-Delile

I-Niacin uhlobo lwevithamini B3. Kutholakala ekudleni okufana nemvubelo, inyama, inhlanzi, ubisi, amaqanda, imifino eluhlaza, nezinhlamvu zokusanhlamvu. INiacin nayo ikhiqizwa emzimbeni kusuka ku-tryptophan, etholakala ekudleni okuqukethe amaprotheni. Uma ithathwa njengesengezo, i-niacin ivame ukutholakala ihlangene namanye amavithamini B.

Ungadidanisi i-niacin ne-NADH, niacinamide, inositol nicotinate, IP-6, noma i-tryptophan. Bona izinhlu ezihlukile zalezi zihloko.

Amafomu kadokotela we-niacin avunywa yi-US Food and Drug Administration (FDA) ye-cholesterol ephezulu nokwandisa amazinga ohlobo oluthile lwe-cholesterol enhle, eyaziwa njenge-HDL. Izithako ze-Niacin nemikhiqizo kadokotela nayo ithathwa ngomlomo ukuvikela ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze I-NIACIN zimi kanje:


Cishe iyasebenza ...

  • Amazinga angajwayelekile we-cholesterol noma amafutha egazi (i-dyslipidemia). Eminye imikhiqizo ye-niacin ivunywa yi-U.S. Food and Drug Administration (FDA) njengemikhiqizo kadokotela yokwelapha amazinga angajwayelekile wamafutha egazi. Le mikhiqizo ye-niacin kadokotela imane iza ngamandla aphezulu ka-500 mg noma ngaphezulu. Izinhlobo zokwengezelwa ekudleni kwe-niacin zivame ukuza ngamandla ka-250 mg noma ngaphansi. Njengoba imithamo ephezulu kakhulu ye-niacin iyadingeka ekuthuthukiseni amazinga e-cholesterol, i-niacin yokudla edliwayo ngokuvamile ayifanele. I-Niacin ingahlanganiswa nezinye izidakamizwa ezehlisa i-cholesterol lapho ukudla kanye nokwelashwa kwesidakamizwa esisodwa kunganele. I-Niacin ithuthukisa amazinga e-cholesterol, kepha ayithuthukisi imiphumela yenhliziyo efana nokuhlaselwa yinhliziyo nokushaywa unhlangothi.
  • Isifo esidalwa ukushoda kwe-niacin (pellagra). I-Niacin ivunyelwe yi-U.S. Food and Drug Administration (FDA) yalokhu kusetshenziswa. Kodwa-ke, i-niacin ingadala "ukuqhuma" (ububomvu, ukulunywa, nokuhayiza). Ngakho-ke omunye umkhiqizo, obizwa nge-niacinamide, kwesinye isikhathi uyathandwa ngoba awubangeli lo mphumela oseceleni.

Kungenzeka kusebenze ...

  • Amazinga angajwayelekile amafutha egazi kubantu abane-HIV / AIDS. Ukuthatha i-niacin kubonakala kuthuthukisa amazinga e-cholesterol namafutha egazi abizwa nge-triglycerides ezigulini ezikulesi simo.
  • Ukuqoqwa kwezimpawu ezandisa ubungozi besifo sikashukela, isifo senhliziyo, nesifo sohlangothi (isifo se-metabolic syndrome). Ukuthatha i-niacin kubonakala kukhuphula amazinga e-high-density lipoprotein (HDL noma "okuhle") cholesterol futhi kunciphise amazinga amafutha egazi abizwa nge-triglycerides kubantu abane-metabolic syndrome. Ukuthatha i-niacin kanye ne-omega-3 fatty acid kadokotela kubonakala kusebenza kangcono kakhulu.

Akusebenzi ...

  • Isifo senhliziyo. Ucwaningo lwekhwalithi ephezulu lukhombisa ukuthi i-niacin ayivimbeli isifo senhliziyo noma isifo sohlangothi kubantu abathatha i-niacin ukuvimbela noma ukwelapha isifo senhliziyo. INiacin nayo ayikhonjiswanga ukunciphisa ubungozi bokufa. I-Niacin akufanele ithathwe ukwelapha noma ukuvimbela isifo senhliziyo.

Ubufakazi obanele bokukala ukusebenza kwe ...

  • Ukuqina kwemithambo yegazi (i-atherosclerosis). Ukuthatha i-niacin ngomlomo kanye nemithi ebizwa nge-bile acid sequestrants kunganciphisa ukuqina kwemithambo emadodeni analesi simo. Kubonakala kusebenza kahle emadodeni anamafutha aphezulu egazi abizwa nge-triglycerides. Kepha ukuthatha i-niacin kubonakala kunganciphisi ukuqina kwemithambo yegazi ezigulini ezinesimo esibizwa nge-peripheral arterial disease (PAD). Futhi, i-niacin ayivimbeli izehlakalo zenhliziyo ezifana nokuhlaselwa yinhliziyo noma isifo sohlangothi.
  • Isifo i-Alzheimer. Abantu abadla inani eliphakeme le-niacin ekudleni nakuma-multivitamin babonakala benengozi engezansi yokuthola isifo se-Alzheimer kunabantu abadla i-niacin encane. Kepha abukho ubufakazi bokuthi ukuthatha isithasiselo se-niacin kuyasiza ukuvimbela isifo se-Alzheimer.
  • Isifo senkwethu. Abantu abadla ukudla okuphezulu nge-niacin bangase babe nethuba elincishisiwe lokuthuthukisa ukonakala kwenyukliya. I-Nuclear cataract uhlobo oluvame kakhulu lwe-cataract. Umphumela wokuthatha isengezo se-niacin awaziwa.
  • Ukutheleleka kwamathumbu okubangela isifo sohudo (ikholera). Ukuthatha i-niacin ngomlomo kubonakala kunciphisa isifo sohudo kubantu abanekholera.
  • Ukungasebenzi kwe-Erectile (ED). Ukuthatha i-niacin ekhishwe isikhathi eside ngesikhathi sokulala amasonto e-12 kubonakala kusiza amadoda ane-ED namazinga aphezulu e-lipid agcine ukwakhiwa ngesikhathi sokuya ocansini.
  • Izinga eliphakeme le-phosphate egazini (hyperphosphatemia). Abantu abanokwehluleka kwezinso bangaba namazinga aphezulu egazi e-phosphate. Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin kunganciphisa amazinga egazi e-phosphate kubantu abanezifo zezinso zokugcina kanye namazinga aphezulu we-phosphate yegazi. Kepha olunye ucwaningo lukhombisa ukuthi ukuthatha i-niacin akwehlisi amazinga e-phosphate egazi kubantu abasebenzisa nemithi esetshenziselwa ukwehlisa amazinga e-phosphate egazi.
  • Ukuvaleka komthambo esweni (ukuvalwa kwe-vein retinal): Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin kungahle kuthuthukise ukubona kwabantu kubantu abanalesi simo.
  • Isifo se-Sickle cell: Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-niacin akuwenzi ngcono amazinga amafutha egazi kubantu abane-sickle cell disease.
  • Izinduna.
  • Ukuphazamiseka kokusebenzisa utshwala.
  • Ukusebenza kwezemidlalo.
  • Ukunakwa kokushoda-i-hyperactivity disorder (ADHD).
  • Ukucindezeleka.
  • Isiyezi.
  • Imibono emibono yezidakamizwa.
  • Migraine.
  • Ukugula kokunyakaza.
  • Ischizophrenia.
  • Ezinye izimo.
Kudingeka ubufakazi obuningi ukukala i-niacin yalokhu kusetshenziswa.

INiacin imuncwa ngumzimba lapho ichithwa emanzini futhi ithathwa ngomlomo. Ishintshelwa ku-niacinamide uma ithathwa ngamanani amakhulu kunalokho okudingeka emzimbeni.

I-Niacin iyadingeka ekusebenzeni okufanele kwamafutha noshukela emzimbeni nokugcina amaseli aphilile. Emithamo ephezulu, i-niacin ingasiza abantu abanesifo senhliziyo ngenxa yemiphumela yayo ezuzisayo ekunqandeni. Kungaphinde kuthuthukise amazinga ohlobo oluthile lwamafutha abizwa nge-triglycerides egazini.

Ukushoda kwe-Niacin kungadala isimo esibizwa nge-pellagra, esidala ukucasuka kwesikhumba, isifo sohudo kanye nokuwohloka komqondo. I-Pellagra yayivamile ekuqaleni kwekhulu lama-20, kepha ayisajwayelekile kakhulu manje, ngoba okunye ukudla okuqukethe ufulawa manje sekuqiniswe nge-niacin. IPellagra isuswe cishe emasikweni asentshonalanga.

Abantu abanokudla okungafanele, ukuphuza ngokweqile, kanye nezinye izinhlobo zezimila ezikhula kancane ezibizwa ngokuthi izicubu ze-carcinoid zingaba sengozini yokushoda kwe-niacin. Lapho ithathwa ngomlomo: UNiacin unjalo CISHE UVIKILE kubantu abaningi lapho bethathwe ngokufanele. Imikhiqizo kadokotela equkethe i-niacin iphephile uma ithathwa njengokuyalelwa. Ukudla okuqukethe i-Niacin noma izithasiselo ze-niacin ziphephile lapho zithathwa ngemithamo engaphansi kuka-35 mcg nsuku zonke.

Umphumela ovamile we-niacin ukusabela okweqile. Lokhu kungadala ukushisa, ukuqaqamba, ukulunywa, nokubomvu kobuso, izingalo, nesifuba, kanye nekhanda. Ukuqala ngemithamo emincane ye-niacin nokuthatha ama-aspirin angama-325 mg ngaphambi komthamo ngamunye we-niacin kuzosiza ukunciphisa ukusabela kokugobhoza. Imvamisa, lokhu kusabela kuyaphela njengoba umzimba ujwayela umuthi. Utshwala bungenza ukusabela okugijimayo kube kubi kakhulu. Gwema inani elikhulu lotshwala ngenkathi uthatha i-niacin.

Eminye imiphumela emibi emibi ye-niacin ukucasuka kwesisu, igesi emathunjini, isiyezi, ubuhlungu emlonyeni nezinye izinkinga.

Lapho kuthathwa imithamo engaphezu kuka-3 amagremu ngosuku lwe-niacin, imiphumela emibi kakhulu ingenzeka. Lokhu kufaka phakathi izinkinga zesibindi, i-gout, izilonda zomgudu wokugaya ukudla, ukungaboni kahle, ushukela ophakeme wegazi, ukushaya kwenhliziyo okungajwayelekile, nezinye izinkinga ezinkulu.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: UNiacin unjalo CISHE UVIKILE kwabesifazane abakhulelwe nabancelisayo lapho bethathwa ngomlomo ngamanani anconyiwe. Inani eliphakanyisiwe le-niacin labesifazane abakhulelwe noma abancelisa ibele lingu-30 mg ngosuku kwabesifazane abangaphansi kweminyaka engu-18 ubudala, kanye no-35 mg wabesifazane abaneminyaka engaphezu kwengu-18.

Izingane: UNiacin unjalo CISHE UVIKILE lapho ithathwa ngomlomo ngamanani anconyiwe eqembu ngalinye leminyaka. Kepha izingane kufanele zigweme ukuthatha imithamo ye-niacin ngaphezu kwemikhawulo ephezulu yansuku zonke, eyi-10 mg yezingane ezineminyaka engu-1-3 ubudala, i-15 mg yezingane ezineminyaka engu-4-8 ubudala, i-20 mg yezingane ezineminyaka engu-9-13, kanye 30 mg wezingane ezineminyaka engu-14-18 ubudala.

Ukungezwani komzimba: I-Niacin ingase yenze ukungezwani komzimba kubhebhethekise i-histamine, ikhemikhali elibhekele izimpawu zomzimba, ukuthi ikhishwe.

Isifo senhliziyo / i-angina engazinzile: Inani elikhulu le-niacin lingakhuphula ubungozi bokushaya kwenhliziyo okungajwayelekile. Sebenzisa ngokuqapha.

Isifo seCrohnAbantu abanesifo sikaCrohn bangaba namazinga aphansi e-niacin futhi badinge ukwengezwa ngesikhathi sokuqhuma.

Isifo sikashukela: I-Niacin ingakhuphula ushukela wegazi. Abantu abanesifo sikashukela abathatha i-niacin kufanele bahlole ushukela egazini labo ngokucophelela.

Isifo se-gallbladder: I-Niacin ingenza isifo se-gallbladder sibe sibi kakhulu.

Gout: Inani elikhulu le-niacin lingaletha ku-gout.

Isifo sezinso: I-Niacin ingaqongelela kubantu abanesifo sezinso. Lokhu kungadala ingozi.

Isifo sesibindi: I-Niacin ingakhuphula ukulimala kwesibindi. Ungasebenzisi amanani amakhulu uma unesifo sesibindi.

Izilonda zesisu noma zamathumbu: I-Niacin ingenza izilonda zibe zimbi kakhulu. Ungasebenzisi amanani amakhulu uma unezilonda.

Umfutho wegazi ophansi kakhulu: I-Niacin inganciphisa umfutho wegazi futhi yenze isimo sibe sibi kakhulu.

Ukuhlinzwa: I-Niacin ingaphazamisa ukulawulwa kukashukela egazini ngesikhathi nangemva kokuhlinzwa. Yeka ukuthatha i-niacin okungenani amasonto ama-2 ngaphambi kokuhlinzwa okuhleliwe.

Amafutha afaka azungeze imisipha (tendon xanthomas): I-Niacin ingakhuphula ubungozi bokutheleleka kuma-xanthomas.

Izinkinga ze-thyroid: I-Thyroxine iyi-hormone ekhiqizwa yindlala yegilo. I-Niacin ingehlisa amazinga egazi e-thyroxine. Lokhu kungabhebhethekisa izimpawu zezifo ezithile ze-thyroid.

Maphakathi
Qaphela ngale nhlanganisela.
Utshwala (i-Ethanol)
I-Niacin ingadala ukugeleza nokuchachamba. Ukuphuza utshwala kanye ne-niacin kungenza ukuqhuma nokushaywa kube kubi kakhulu. Kukhona nokunye ukukhathazeka ngokuthi ukuphuza utshwala nge-niacin kungakhuphula amathuba okuba nomonakalo wesibindi.
I-Allopurinol (iZyloprim)
I-Allopurinol (iZyloprim) isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-allopurinol (iZyloprim).
I-Clonidine (Catapres)
I-Clonidine ne-niacin yomibili ingcindezi yegazi ephansi. Ukuthatha i-niacin ne-clonidine kungadala ukuthi umfutho wegazi lakho ube phansi kakhulu.
I-Gemfibrozil (Lopid)
Ukuthatha i-niacin kanye ne-gemfibrozil kungadala ukulimala kwemisipha kwabanye abantu. Sebenzisa ngokuqapha.
Imithi yesifo sikashukela (Imithi elwa nesifo sikashukela)
Ukusetshenziswa kwemithamo ephezulu ye-niacin (cishe u-3-4 amagremu nsuku zonke) kungakhuphula ushukela wegazi. Ngokwandisa ushukela wegazi, i-niacin inganciphisa ukusebenza kwemithi yesifo sikashukela. Bheka ushukela wegazi lakho eduze. Umthamo wemithi yakho yesifo sikashukela ungadinga ukuguqulwa.

Eminye imithi esetshenziselwa isifo sikashukela ifaka i-glimepiride (Amaryl), i-glyburide (i-DiaBeta, i-Glynase PresTab, i-Micronase), i-insulin, i-pioglitazone (i-Actos), i-rosiglitazone (i-Avandia), i-metformin (i-Glucophage), i-nateglinide (i-Starlix), i-repaglinide (i-Prandin), i-chlorpropamide (i-chlorpropamide) I-Diabinese), i-glipizide (iGlucotrol), i-tolbutamide (i-Orinase), nabanye.
Imithi yokwelapha umfutho wegazi ophakeme (Imithi efuthayo)
Ukusebenzisa i-niacin nezidakamizwa ezehlisa umfutho wegazi kungakhuphula imiphumela yale mithi futhi kungehlise umfutho wegazi kakhulu.

Eminye imishanguzo yomfutho wegazi ophakeme ihlanganisa i-captopril (Capoten), i-enalapril (i-Vasotec), i-losartan (i-Cozaar), i-valsartan (i-Diovan), i-diltiazem (i-Cardizem), i-amlodipine (i-Norvasc), i-hydrochlorothiazide (i-HydroDIURIL), i-furosemide (i-Lasix), neminye eminingi .
Imithi engalimaza isibindi (izidakamizwa ze-Hepatotoxic)
I-Niacin ingalimaza isibindi. Amalungiselelo e-niacin akhululwa aqinile abonakala enengozi enkulu kakhulu. Ukuthatha i-niacin kanye nemithi engalimaza nesibindi kungakhuphula ubungozi bokulimala kwesibindi. Ungathathi i-niacin uma uthatha umuthi ongalimaza isibindi.

Eminye imishanguzo engalimaza isibindi ifaka i-acetaminophen (Tylenol neminye), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporaconazole) i-erythromycin (i-Erythrocin, i-Ilosone, abanye), i-phenytoin (i-Dilantin), i-lovastatin (i-Mevacor), i-pravastatin (i-Pravachol), i-simvastatin (i-Zocor), nezinye eziningi.
Imithi eyehlisa ukunqamuka kwegazi (Anticoagulant / Antiplatelet drug)
I-Niacin inganciphisa ukuvimba kwegazi. Ukuthatha i-niacin kanye nemithi nayo ejija kancane ukuvimba kungandisa amathuba okulinyazwa nokopha.

Eminye imithi eyehlisa ijubane ukuvala igazi ifaka phakathi i-aspirin, i-clopidogrel (i-Plavix), i-dalteparin (i-Fragmin), i-enoxaparin (i-Lovenox), i-heparin, i-indomethacin (i-Indocin), i-ticlopidine (i-Ticlid), i-warfarin (i-Coumadin), neminye.
Imithi esetshenziselwa ukwehlisa i-cholesterol (i-Bile acid sequestrants)
Eminye imishanguzo yokwehlisa i-cholesterol ebizwa nge-bile acid sequestrants inganciphisa ukuthi i-niacin engakanani emzimbeni oyiphuzayo. Lokhu kunganciphisa ukusebenza kwe-niacin. Thatha i-niacin kanye nemithi okungenani amahora angama-4-6 ahlukene.

Eminye yale mithi esetshenziselwa ukwehlisa i-cholesterol ifaka phakathi i-cholestyramine (i-Questran) ne-colestipol (i-Colestid).
Imithi esetshenziselwa ukwehlisa i-cholesterol (ama-Statins)
I-Niacin ingathinta kabi imisipha. Eminye imithi esetshenziselwa ukwehlisa i-cholesterol ebizwa ngama-statins nayo ingathinta imisipha. Ukuthatha i-niacin kanye nale mithi kungakhuphula ubungozi bezinkinga zemisipha.

Eminye yale mithi esetshenziselwa i-cholesterol ephezulu ifaka i-rosuvastatin (Crestor), i-atorvastatin (i-Lipitor), i-lovastatin (i-Mevacor), i-pravastatin (i-Pravachol), i-fluvastatin (i-Lescol), ne-simvastatin (i-Zocor).
I-Probenecid (Benemid)
I-Probenecid isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-probenecid.
I-Sulfinpyrazone (Anturane)
I-Sulfinpyrazone (Anturane) isetshenziselwa ukwelapha i-gout. Ukuthatha imithamo emikhulu ye-niacin kungalimaza i-gout futhi kwehlise ukusebenza kwe-sulfinpyrazone (Anturane).
Indlala yegilo
Umzimba ngokwemvelo ukhiqiza ama-hormone e-thyroid. I-Niacin inganciphisa amazinga e-hormone ye-thyroid. Ukuthatha i-niacin ngamaphilisi e-hormone yegilo kunganciphisa imiphumela kanye nemiphumela emibi yehomoni yegilo.
Okuncane
Qaphela ngale nhlanganisela.
I-Aspirin
I-Aspirin ivame ukusetshenziswa ne-niacin ukunciphisa ukuqhuma okubangelwa yi-niacin. Ukuthatha imithamo ephezulu ye-aspirin kunganciphisa ukuthi umzimba ususa kanjani i-niacin ngokushesha okukhulu. Lokhu kungadala ukuthi kube ne-niacin eningi kakhulu emzimbeni futhi kungaholela emiphumeleni emibi. Kodwa-ke, imithamo ephansi ye-aspirin esetshenziswa kakhulu ukugeleza okuhlobene ne-niacin akubonakali kuyinkinga.
Isichibi seNicotine (Nicoderm)
I-Niacin kwesinye isikhathi ingadala ukugeleza nesiyezi. Isiqephu se-nicotine naso singadala ukugeleza nesiyezi. Ukuthatha i-niacin noma i-niacinamide nokusebenzisa isichibi se-nicotine kungakhuphula amathuba okuba ugcwale futhi ube nesiyezi.
I-Beta-carotene
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-beta-carotene, kubonakala ngathi kwenza lokhu kuphakama kwe-HDL kube lula. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
I-Chromium
Ukuthatha i-niacin ne-chromium ndawonye kunganciphisa ushukela wegazi. Uma unesifo sikashukela futhi uthatha izithako ze-chromium ne-niacin ndawonye, ​​qapha ushukela wegazi lakho ukuze uqiniseke ukuthi awubi phansi kakhulu.
Amakhambi nezithako ezingalimaza isibindi
I-Niacin, ikakhulukazi ngemithamo ephakeme ingadala ukulimala kwesibindi. Ukuthatha i-niacin kanye namanye amakhambi noma izithasiselo ezingalimaza isibindi kungakhuphula le ngozi. Eminye yale mikhiqizo ifaka i-androstenedione, iqabunga le-borage, i-chaparral, i-comfrey, i-dehydroepiandrosterone (i-DHEA), i-germander, i-kava, i-pennyroyal oil, imvubelo ebomvu, neminye.
Amakhambi nezengezo ezinganciphisa umfutho wegazi
I-Niacin inganciphisa umfutho wegazi. Ukuthatha i-niacin namanye amakhambi nezithasiselo nazo ezinciphisa umfutho wegazi kungadala ukuthi umfutho wegazi wehle kakhulu. Amanye amakhambi nezithasiselo ezinganciphisa umfutho wegazi zifaka i-andrographis, i-casein peptides, uzipho lwekati, i-coenzyme Q10, i-L-arginine, i-lycium, i-nettle ehlabayo, i-theanine, nezinye.
Amakhambi nezengezo ezinganciphisa ukujiya kwegazi
I-Niacin inganciphisa ukuvimba kwegazi. Ukusebenzisa i-niacin kanye namanye amakhambi kanye nezithasiselo nazo ezihamba kancane ekunqandeni kwegazi kungakhuphula ingozi yokopha kwabanye abantu. Amanye amakhambi alolu hlobo afaka i-angelica, i-clove, i-danshen, i-garlic, i-ginger, i-Panax ginseng, namanye.
Itiye likaKombucha
Kukhona ukukhathazeka okuthile ngokuthi itiye le-kombucha linganciphisa ukumuncwa kwe-niacin. Noma kunjalo, lokhu kudinga ukufundwa kabanzi.
Selenium
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-selenium, kubonakala sengathi kubangela lokhu kuphakama kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
I-Tryptophan
Amanye ama-tryptophan kusuka ekudleni angaguqulwa abe yi-niacin emzimbeni. Ukuthatha i-niacin ne-tryptophan ndawonye kungakhuphula amazinga nemiphumela emibi ye-niacin.
Uvithamini C
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-vitamin C, kubonakala sengathi kubangela lokhu kukhuphuka kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
Uvithamini E
Inhlanganisela ye-niacin kanye nemithi kadokotela simvastatin (Zocor) inyusa i-HDL (high density lipoprotein) cholesterol ("cholesterol enhle") kubantu abanesifo senhliziyo namazinga aphansi e-HDL. Kodwa-ke, ukuthatha i-niacin kanye nezinhlanganisela zama-antioxidants, kufaka phakathi i-vitamin E, kubonakala sengathi kubangela lokhu kuphakama kwe-HDL. Akwaziwa noma lo mphumela uyenzeka kubantu abangenaso isifo senhliziyo.
Izinki
Umzimba ungenza i-niacin. Abantu abangondlekile futhi abanenkinga ye-niacin, njengezidakwa ezingapheli, benza i-niacin eyengeziwe uma bethatha i-zinc. Kungaba nobungozi obandayo bemiphumela emibi ehlobene ne-niacin njengokushaywa nokushaywa uma i-niacin ne-zinc zithathwa ndawonye.
Iziphuzo ezishisayo
I-Niacin ingadala ukugeleza nokuheha. Le miphumela ingakhuphuka uma i-niacin ithathwa ngesiphuzo esishisayo.
Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

ABADALA

NGOMLOMO:
  • Jikelele: Olunye uhlu lwemikhiqizo yokwengeza yokudla lubala i-niacin kulebula ngokulingana kwe-niacin (NE). 1 mg we-niacin uyefana no-1 mg NE. Lapho i-niacin ifakwa kuhlu kwelebula njenge-NE, ingafaka nezinye izinhlobo ze-niacin futhi, kufaka phakathi i-niacinamide, i-inositol nicotinate, ne-tryptophan. Izibonelelo zokudla ezinconywayo zansuku zonke (RDAs) ze-niacin kubantu abadala zingama-16 mg NE kwabesilisa, i-14 mg NE yabesifazane, i-18 mg NE yabesifazane abakhulelwe, ne-17 mg NE yabesifazane abancelisayo.
  • Nge-cholesterol ephezulu: Imiphumela ye-niacin incike kumthamo. Amanani we-niacin aphansi njengo-50 mg futhi asetshenziswe njengama-gramu ayi-12 usuku ngalunye asetshenzisiwe. Kodwa-ke, ukwanda okukhulu kwe-HDL nokuncipha kwe-triglycerides kwenzeka ngo-1200 kuye ku-1500 mg / ngosuku. Imiphumela emikhulu ye-Niacin ku-LDL yenzeka ngo-2000 kuye ku-3000 mg / ngosuku. I-Niacin ivame ukusetshenziswa neminye imithi yokwenza ngcono amazinga e-cholesterol.
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra: 300-1000 mg nsuku zonke ngemithamo ehlukanisiwe.
  • Okwelapha ukuqina kwemithambo yegazi: Amanani we-niacin abe phezulu njengama-gramu ayi-12 nsuku zonke. Kodwa-ke, umthamo ongaba u-1 kuye ku-4 amagremu we-niacin nsuku zonke, uwedwa noma kanye nama-statins noma i-bile acid sequestrants (umuthi owehlisa i-cholesterol), usetshenziselwe iminyaka engafika kwengu-6.2.
  • Ukwehlisa ukulahleka koketshezi okubangelwa ubuthi bekholeraKusetshenziswe amagremu ama-2 nsuku zonke.
  • Ngamazinga angavamile egazi ngenxa yokwelashwa kwe-HIV / AIDSKusetshenziswe ama-gramu ama-2 nsuku zonke.
  • Nge-metabolic syndrome: 2 amagremu we-niacin athathwe nsuku zonke amasonto ayi-16. Kwezinye izimo, i-niacin 2 gram nsuku zonke, iyodwa noma ngalesi silinganiso, ithathwa kanye no-4 amagremu we-omega-3 ethyl esters kadokotela (Lovaza, GlaxoSmithKline Pharmaceuticals).
NGU-IV:
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagraKusetshenziswe i-60 mg ye-niacin.
NJENGOBA ISITHOMBE:
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagraKusetshenziswe i-60 mg ye-niacin.
IZINGANE

NGOMLOMO:
  • Jikelele: Izibonelelo zokudla ezinconywayo zansuku zonke (ama-RDA) ze-niacin ezinganeni zingu-2 mg NE wezinsana ezinezinyanga ezineminyaka engu-0-6, i-4 mg NE yezinsana ezinezinyanga eziyi-7-12 ubudala, i-6 mg NE yezingane ezineminyaka engu-1-3, I-8 mg NE yezingane ezineminyaka engu-4-8 ubudala, i-12 mg NE yezingane ezineminyaka engu-9-13 ubudala, i-16 mg NE yabafana abaneminyaka engu-14-18 ubudala, ne-14 mg NE yamantombazane aneminyaka engu-14-18 ubudala.
  • Ukuvimbela nokwelapha ukuntuleka kukavithamini B3 nezimo ezihlobene ne-pellagra: 100-300 mg ngosuku lwe-niacin, enikezwa ngemithamo ehlukanisiwe.
3-Pyridinecarboxylic Acid, Acide Nicotinique, Acide Pyridine-Carboxylique-3, Anti-Blacktongue Factor, Antipellagra Factor, B Complex Vitamin, Complexe de Vitamines B, Facteur Anti-Pellagre, Niacina, Niacine, Nicosedine, Nicotinra Aciding, I-Nicotinic Aciding, I-Nicotinra Acid Vitamin B3, Vitamin PP, Vitamina B3, Vitamine B3, Vitamine PP.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.


  1. UAnderson TJ, uGrégoire J, uPearson GJ, et al. Imihlahlandlela Yenhlangano Yezinhliziyo Yezinhliziyo ZaseCanada ka-2016 Yokuphathwa Kwe-Dyslipidemia Yokuvimbela Isifo Senhliziyo Kumuntu Omdala. Can J Cardiol. 2016; 32: 1263-1282. Buka okungaqondakali.
  2. UStone NJ, uRobinson JG, uLichtenstein AH, et al. Umhlahlandlela we-ACC / AHA ka-2013 ekwelapheni i-cholesterol egazini ukunciphisa ingozi ye-atherosclerotic yenhliziyo kubantu abadala: umbiko weqembu le-American College of Cardiology / American Heart Association ngeziqondiso zokusebenza. UJ Am Coll Cardiol 2014; 63: 2889-934. Buka okungaqondakali.
  3. ULloyd-Jones DM, uMorris PB, uBallantyne CM, et al. Isinqumo sokuvumelana kwesazi se-ACC se-ACC endimeni yezindlela ezingezona eze-statin zokwelashwa kwe-LDL-cholesterol ekwehliseni ukuphathwa kwe-atherosclerotic cardiovascularisifo sengozi: umbiko weqembu laseMelika College of Cardiology emibhalweni yochwepheshe bemitholampilo. UJ Am Coll weCardiol 2016; 68: 92-125. Buka okungaqondakali.
  4. UMontserrat-de la Paz S, uLopez S, uBermudez B, et al. Imiphumela ye-niacin ekhishwa ngokushesha kanye nama-acid okunamafutha ekudleni kwe-insulin enamandla kanye nesimo se-lipid kubantu abane-metabolic syndrome. J Sci Ukudla Agric 2018; 98: 2194-200. Buka okungaqondakali.
  5. UJenkins DJA, Spence JD, Giovannucci EL, et al. Amavithamini engeziwe kanye namaminerali okuvimbela nokwelashwa kwe-CVD. UJ Am Coll Cardiol 2018; 71: 2570-84. Buka okungaqondakali.
  6. USahebkar A, uReiner Z, uSimental-Mendia LE, uFerretti G, uCicero AF. Umphumela we-niacin ekhishwe isikhathi eside kumazinga e-plasma lipoprotein (a): Ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kwezilingo ezilawulwa ngokungahleliwe ze-placebo. Umzimba. 2016 Nov; 65: 1664-78. Buka okungaqondakali.
  7. UGaynon MW, uPaulus YM, uRahimy E, u-Alexander JL, uMansour SE. Umphumela we-niacin yomlomo ekuvalekeni kwe-vein central retinal. Amathuna i-Arch Clin Exp Ophthalmol. 2017 Juni; 255: 1085-92. Buka okungaqondakali.
  8. USchandelmaier S, uBriel M, uSaccilotto R, u-Olu KK, u-Arpagaus A, uHemkens LG, uNordmann AJ. I-Niacin yokuvimbela okuyisisekelo nokwesibili kwemicimbi yenhliziyo. ICochrane Database Syst Rev. 2017 Jun 14; 6: CD009744. Buka okungaqondakali.
  9. ULin C, uGraninetti A, uShikuma C, et al. Imiphumela yokukhishwa kwe-niacin enwetshiwe kuma-lipoprotein sub-particle concentrations ezigulini ezinegciwane lesandulela ngculaza. IHawaii J Med Impilo Yomphakathi. 2013 Ephreli; 72: 123-7. Buka okungaqondakali.
  10. UScoffone HM, uKrajewski M, uZorca S, et al. Umphumela we-niacin ekhishwe isikhathi eside kuma-serum lipids nasemsebenzini we-endothelial kubantu abadala abane-sickle cell anemia kanye namazinga aphansi we-lipoprotein cholesterol. NginguJ Cardiol. 2013 Nov 1; 112: 1499-504. Buka okungaqondakali.
  11. UBrunner G, Yang EY, Kumar A, et al. Umphumela wokuguqulwa kwe-lipid kwisifo semithambo yomzimba ngemuva kwesilingo sokungenelela kwe-endovascular (ELIMIT). I-atherosclerosis. 2013 Dis; 213: 371-7. Buka okungaqondakali.
  12. UGoldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Ukwelashwa kwe-Niacin kanye nengozi yesifo sikashukela esisha: ukuhlaziywa kwe-meta kwezilingo ezilawulwa ngokungahleliwe. Inhliziyo. 2016 Feb; 102: 198-203. Buka okungaqondakali.
  13. Idokhumenti ye-PL, Indima Yezinto Ezingezona Izitatimende zeDyslipidemia. Incwadi KaPhemistri / Incwadi KaPrescriber. Juni 2016; 32: 320601.
  14. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE; Abaphenyi be-AIM-HIGH. Ukwelashwa kwe-niacin enwetshiwe kanye nobungozi bokushaywa yischemic ezigulini ezinesifo senhliziyo: i-Atherothrombosis Intervention in Metabolic Syndrome ene-HDL / High Triglycerides: Impact ku-Global Health Outcome (AIM-HIGH). Unhlangothi. 2013 Okthoba; 44: 2688-93. Buka okungaqondakali.
  15. UShearer GC, uPottala JV, uHansen SN, uBrandenburg V, uHarris WS. Imiphumela ye-niacin kadokotela ne-omega-3 fatty acids kuma-lipids nomsebenzi we-vascular ku-metabolic syndrome: isilingo esilawulwa ngokungahleliwe. J Lipid Res. 2012 uNov; 53: 2429-35. Buka okungaqondakali.
  16. ISazonov V, iMaccubbin D, iSisk CM, iCanner PL. Imiphumela ye-niacin ekwenzekeni kwesifo sikashukela esisha kanye nemicimbi yenhliziyo ezigulini ezine-normoglycaemia kanye ne-glucose yokuzila engasebenzi kahle. I-Int J Clin Pract. 2013 Ephreli; 67: 297-302. Buka okungaqondakali.
  17. UPhilpott AC, uHubacek J, uSun YC, uHillard D, noAnderson TJ. I-Niacin ithuthukisa iphrofayli ye-lipid kepha hhayi ukusebenza kwe-endothelial ezigulini ezinesifo semithambo yenhliziyo ekwelashweni okuphezulu kwe-statin therapy. I-atherosclerosis. 2013 Feb; 226: 453-8. Buka okungaqondakali.
  18. ULoebl T, Raskin S. Umbiko wecala lenoveli: isiqephu esibuhlungu se-manic psychotic ngemuva kokwelashwa nge-niacin. Umtholampilo waseJ Neuropsychiatry Neurosci. Ukuwa kuka-2013; 25: E14. Buka okungaqondakali.
  19. UNdunankulu waseLavigne, uKaras RH. Isimo samanje se-niacin ekuvimbeleni izifo zenhliziyo: ukubuyekezwa okuhlelekile kanye ne-meta-regression. UJ Am Coll Cardiol. 2013 uJan 29; 61: 440-6. Buka okungaqondakali.
  20. ILakey WC, iGreyshock N, iGuyton JR. Ukusabela okungahambi kahle kwe-Achilles tendon xanthomas ezigulini ezintathu ze-hypercholesterolemic ngemuva kokuqiniswa kokwelashwa nge-niacin ne-bile acid sequestrants. J Clin Lipidol. 2013 Mar-Ephreli; 7: 178-81. Buka okungaqondakali.
  21. UKei A, Liberopoulos EN, Mikhailidis DP, Elisaf M. Ukuqhathaniswa kokushintshela kumthamo ophakeme kakhulu we-rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. I-Int J Clin Pract. 2013 Meyi; 67: 412-9. Buka okungaqondakali.
  22. UKeene D, Intengo C, uShun-Shin MJ, uFrancis DP. Imiphumela engcupheni yenhliziyo yemithambo yokwelashwa okuphezulu okubhekiswe ekwelapheni i-niacin, fibrate, kanye ne-CETP inhibitors: ukuhlaziywa kwe-meta kokuhlolwa okungahleliwe okulawulwa okubandakanya iziguli eziyi-117,411. BMJ. 2014 Julayi 18; 349: g4379. Buka okungaqondakali.
  23. Yena YM, Feng L, Huo DM, Yang ZH, Liao YH. Izinzuzo nokulimala kwe-niacin kanye ne-analog yayo yeziguli ze-renal dialysis: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Int Urol Nephrol. 2014 Feb; 46: 433-42. Buka okungaqondakali.
  24. UGuyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM. Umphumela we-niacin ekhishwe isikhathi eside kusifo sikashukela esisha phakathi kweziguli ze-hyperlipidemic eziphathwe nge-ezetimibe / simvastatin esivivinyweni esilawulwa ngokungahleliwe. Ukunakekelwa yisifo sikashukela. 2012 Ephreli; 35: 857-60. Buka okungaqondakali.
  25. UDavidson MH, uRooney M, uPollock E, uDrucker J, uChoy Y. Umphumela we-colesevelam ne-niacin ku-low-density lipoprotein cholesterol kanye nokulawulwa kwe-glycemic ezifundweni ezine-dyslipidemia kanye ne-glucose yokuzila engasebenzi kahle. J Clin Lipidol. 2013 Septhemba-Oct; 7: 423-32. Buka okungaqondakali.
  26. UBassan M. Icala le-niacin ekhishwa ngokushesha. Umkhuhlane Wenhliziyo. 2012 Jan-Feb; 41: 95-8. Buka okungaqondakali.
  27. I-Aramwit P, i-Srisawadwong R, i-Supasyndh O. Ukusebenza nokuphepha kwe-nicotinic acid ekhishwe isikhathi eside yokwehlisa i-serum phosphorus ezigulini ze-hemodialysis. UJ Nephrol. 2012 uMeyi-Juni; 25: 354-62. Buka okungaqondakali.
  28. U-Ali EH, McJunkin B, Jubelirer S, Hood W. Niacin wenze i-coagulopathy njengesibonakaliso sokulimala kwesibindi semilingo. W V Med J. 2013 Jan-Feb; 109: 12-4 Buka okungaqondakali.
  29. U-Urberg, M., Benyi, J., noJohn, R. Imiphumela ye-Hypocholesterolemic ye-nicotinic acid kanye ne-chromium supplementation. J Fam Khipha. 1988; 27: 603-606. Buka okungaqondakali.
  30. I-Hendrix, i-CR, i-Housh, i-TJ, i-Mielke, i-M, i-Zuniga, i-JM, i-Camic, i-CL, i-Johnson, i-GO, i-Schmidt, i-RJ, ne-Housh, imiphumela emibi ye-DJ yesengezo esiqukethe i-caffeine ekucindezelweni kwebhentshi namandla wokunweba emlenzeni nesikhathi ukukhathala phakathi nomjikelezo we-ergometry. J Amandla.Cond. Res 2010; 24: 859-865. Buka okungaqondakali.
  31. I-Figge HL, i-Figge J, i-Souney PF, et al. Ukuqhathanisa ukukhishwa kwe-nicotinuric acid ngemuva kokungeniswa kwamalungiselelo e-nicotinic acid amabili alawulwayo kumuntu. UJ Clin Pharmacol. Ngo-1988 uDec; 28: 1136-40. Buka okungaqondakali.
  32. UMrochek JE, uJolley RL, i-Young DS, iTurner WJ. Impendulo yeMetabolic yabantu ekufakeni i-nicotinic acid ne-nicotinamide. Umtholampilo Chem. 1976; 22: 1821-7. Buka okungaqondakali.
  33. I-Neuvonen PJ, Roivas L, Laine K, Sundholm O. Ukutholakala kokutholakala kokukhishwa okuqhubekayo kwe-nicotinic acid formulations. UBr J Clin Pharmacol. 1991; 32: 473-6. Buka okungaqondakali.
  34. UMenon RM, u-Adams MH, uGonzález MA, uTolbert DS, uLeu JH, uCefali EA. I-Plasma ne-urine pharmacokinetics ye-niacin kanye nama-metabolite ayo kusuka ekwakhiweni kwe-niacin enwetshiwe. I-Int J Clin Pharmacol Ther. 2007; 45: 448-54. Buka okungaqondakali.
  35. UKarpe F, uFrayn KN. I-nicotinic acid receptor - indlela entsha yomuthi wakudala. I-Lancet. 2004; 363: 1892-4. Buka okungaqondakali.
  36. Amacala S, Smith SJ, Zheng YW, et al. Ukukhonjwa kofuzo olufaka i-acyl CoA: i-diacylglycerol acyltransferase, i-enzyme eyinhloko ekuhlanganisweni kwe-triacylglycerol synthesis. I-Proc Natl Acad Sci U S A. 1998; 95: 13018-23. Buka okungaqondakali.
  37. UGanji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. I-Niacin ngokuncintisana ivimbela i-DGAT2 kepha hhayi umsebenzi we-DGAT1 kumaseli we-HepG2. J Lipid Res. 2004; 45: 1835-45. Buka okungaqondakali.
  38. UTornvall P, uHamsten A, uJohansson J, uCarlson LA. Ukujwayelekile kokwakheka kwe-lipoprotein ephansi kakhulu ku-hypertriglyceridemia yi-nicotinic acid. I-atherosclerosis. 1990; 84 (2-3): 219-27. Buka okungaqondakali.
  39. UMorgan JM, uCapuzzi DM, uBaksh RI, et al. Imiphumela ye-niacin ekhishwe isikhathi eside ekusatshalalisweni kwe-lipoprotein subclass. NginguJ Cardiol. 2003; 91: 1432-6. Buka okungaqondakali.
  40. UJin FY, uKamanna VS, uKashyap ML. I-Niacin inciphisa ukususwa kwe-high-density lipoprotein apolipoprotein A-I kepha hhayi i-cholesterol ester ngamaseli we-Hep G2. Impembelelo yokuthuthwa kwe-cholesterol eguqukayo. I-Arterioscler Thromb Vasc Biol. 1997; 17: 2020-8. Buka okungaqondakali.
  41. UVincent JE, uZijlstra FJ. I-Nicotinic acid ivimbela ukuhlanganiswa kwe-thromboxane kuma-platelets. Ama-Prostaglandins. 1978; 15: 629-36. Buka okungaqondakali.
  42. UDatta S, Das DK, Engelman RM, et al. Ukugcinwa okulondoloziwe kwe-myocardial yi-nicotinic acid, i-antilipolytic compound: indlela yokwenza. I-Basic Res Cardiol. 1989; 84: 63-76. Buka okungaqondakali.
  43. UTurjman N, uCardamone A, uGotterer GS, uHendrix TR. Umphumela we-nicotinic acid ekunyakazeni koketshezi okwenziwe yikholera kanye nokungaguquguquki kwe-sodium flux ku-rabbit jejunum. UJohn Hopkins Med J. 1980; 147: 209-11. Buka okungaqondakali.
  44. U-Unna K. Ucwaningo ngobuthi nangokhemisi we-nicotinic acid. UJ Pharmacol Exp Ther 1939; 65: 95-103.
  45. I-Brazda FG noCoulson RA. Ubuthi be-nicotinic acid nokunye okutholakele kukho. I-Proc Soc Exp Biol Med 1946; 62: 19-20.
  46. UChen KK, uRose CL, uRobbins EB. Ubuthi be-nicotinic acid. I-Proc Soc Exp Biol Med 1938; 38: 241-245.
  47. UFraunfelder FW, uFraunfelder FT, Illingworth DR. Imiphumela emibi ye-ocular ehlotshaniswa nokwelashwa kwe-niacin. UBr J Ophthalmol. 1995; 79: 54-56.
  48. I-Litin SC, no-Anderson CF. I-myopathy ehlobene neNicotinic acid: umbiko wamacala amathathu. NginguJ Med. 1989; 86: 481-3.
  49. UGharavi AG, uDiamond JA, uSmith DA, uPhillips RA. I-myopathy eyenziwe nge-Niacin. NginguJ Cardiol. 1994; 74: 841-2. Buka okungaqondakali.
  50. U-O’REILLY PO, CALLBECK MJ, HOFFER A. Ukukhishwa okuqinisiwe kwe-nicotinic acid (nicospan); umphumela emazingeni e-cholesterol nama-leukocyte. Ingabe uMed Assoc J. 1959; 80: 359-62. Buka okungaqondakali.
  51. Umhlaba TP, Odom L, Mullins CA. I-Lactic acidosis ehambisana nokwelashwa komthamo omkhulu we-niacin. INingizimu Med J. 1991; 84: 496-7. Buka okungaqondakali.
  52. I-Brown WV. I-Niacin yezinkinga ze-lipid. Izinkomba, ukusebenza, nokuphepha. I-Postgrad Med. 1995 Aug; 98: 185-9, 192-3. Buka okungaqondakali.
  53. UWindler E, uZyriax BC, uBamberger C, uRinninger F, uBeil FU. Amasu amanje nentuthuko yakamuva ekwelashweni kwe-hypercholesterolemia. I-Atheroscler Suppl. U-2009; 10: 1-4. Buka okungaqondakali.
  54. UKaijser L, u-Eklund B, u-Olsson AG, uCarlson LA. Ukuhlukaniswa kwemiphumela ye-nicotinic acid ku-vasodilatation ne-lipolysis yi-prostaglandin synthesis inhibitor, indomethacin, kumuntu. IMed Biol. 1979; 57: 114-7. Buka okungaqondakali.
  55. U-Eklund B, uKaijser L, uNowak J, uWennmalm A.I-Prostaglandins inegalelo ekuvuselweni kwe-vasodilation okubangelwa yi-nicotinic acid. Ama-Prostaglandins. 1979; 17: 821-30. Buka okungaqondakali.
  56. U-Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Ucwaningo ngomshini wokukhipha owenziwe yi-nicotinic acid. I-Acta Pharmacol Toxicol (iCopenh). 1977 Jul; 41: 1-10. Buka okungaqondakali.
  57. UMorgan JM, uCapuzzi DM, uGuyton JR, et al. Umphumela Wokwelapha we-Niaspan, i-Niacin ekhishwa elawulwayo, ezigulini ezine-Hypercholesterolemia: Isivivinyo esilawulwa yi-Placebo. UJ Cardiovasc Pharmacol Ther. 1996; 1: 195-202. Buka okungaqondakali.
  58. U-Aronov DM, uKeenan JM, u-Akhmedzhanov NM, et al. Ukuhlolwa komtholampilo kwe-wax-matrix okukhishwa okuqhubekayo kwe-niacin kubantu baseRussia abane-hypercholesterolemia. I-Arch Fam Med. 1996; 5: 567-75. Buka okungaqondakali.
  59. UGoldberg A, Alagona P Jr, uCapuzzi DM, et al. Ukusebenza kwamazinga amaningi nokuphepha kwefomu ekhishwe isikhathi eside ye-niacin ekuphathweni kwe-hyperlipidemia. NginguJ Cardiol. 2000; 85: 1100-5. Buka okungaqondakali.
  60. USmith DT, uRuffin JM, noSmith SG. I-Pellagra yelashwe ngempumelelo nge-nicotinic acid: umbiko wecala. IJAMA 1937; 109: 2054-2055.
  61. UFouts PJ, Helmer OM, Lepkovsky S, no-al. Ukwelashwa kwe-pellagra yomuntu nge-nicotinic acid. I-Proc Soc Exp Biol Med 1937; 37: 405-407.
  62. UBrown BG, uBardsley J, uPoulin D, et al. Umthamo olinganiselwe, ukwelashwa ngezidakamizwa ezintathu nge-niacin, lovastatin, ne-colestipol ukunciphisa i-low-density lipoprotein cholesterol <100 mg / dl ezigulini ezine-hyperlipidemia kanye ne-coronary artery disease. NginguJ Cardiol. 1997; 80: 111-5. Buka okungaqondakali.
  63. I-Ban TA. Izifundo zengqondo nezifundo zemikhakha yezemithi. IProg Neuropsychopharmacol Biol Psychiatry. Ngo-2006 Meyi; 30: 429-41.
  64. ULanska DJ. Isahluko 30: Izici zomlando zokuphazamiseka okukhulu kwamavithamini wezinzwa: amavithamini B ancibilikayo emanzini. I-Handb Clin Neurol. 2010; 95: 445-76. Buka okungaqondakali.
  65. IBerge KG, iCanner PL. Iphrojekthi yezidakamizwa zeCoronary: isipiliyoni nge-niacin. ICoronary Drug Project Group Iqembu. I-Eur J Clin Pharmacol. 1991; 40 Isengezo 1: S49-51. Buka okungaqondakali.
  66. Abekho ababhali abaklelisiwe. I-Clofibrate ne-niacin esifo senhliziyo. JAMA. Ngo-1975 uJan 27; 231: 360-81. Buka okungaqondakali.
  67. UHenkin Y, Oberman A, Hurst DC, Segrest JP. UNiacin uphinde wahlola: ukubonwa komtholampilo ngomuthi obalulekile kepha ongasetshenziswanga. NginguJ Med. 1991; 91: 239-46. Buka okungaqondakali.
  68. UHenkin Y, Johnson KC, Segrest JP. Rechallenge ne-crystalline niacin ngemuva kwe-hepatitis eyenziwe yizidakamizwa kusuka ku-niacin ekhishwe isikhathi eside. JAMA. 1990; 264: 241-3. Buka okungaqondakali.
  69. U-Etchason JA, uMiller TD, uSquires RW, et al. I-hepatitis eyenziwe nge-Niacin: umphumela ongaba khona we-side neacin ekhishwa isikhathi esincane. IMayo Clin Proc. 1991; 66: 23-8. Buka okungaqondakali.
  70. UShakir KM, uKoll S, u-Aprill BS, uDrake AJ 3rd, u-Eisold JF. I-Nicotinic acid inciphisa amazinga e-serum thyroid hormone ngenkathi igcina isimo se-euthyroid. IMayo Clin Proc. 1995; 70: 556-8. Buka okungaqondakali.
  71. UDrinka PJ. Ukuguqulwa kokuhlolwa kokusebenza kwe-thyroid kanye ne-hepatic okuhambisana nokulungiswa kwe-niacin ekhishwa okuqhubekayo. IMayo Clin Proc. 1992; 67: 1206. Buka okungaqondakali.
  72. UCashin-Hemphill L, uSpencer CA, uNicoloff JT, et al. Ukuguqulwa kwezimpawu ze-serum thyroid hormonal nge-colestipol-niacin therapy. U-Ann Intern Med. 1987; 107: 324-9. Buka okungaqondakali.
  73. UDunn RT, iFord MA, iRindone JP, i-Kwiecinski FA. I-Aspirin ephansi ne-Ibuprofen Yehlisa Ukusabela Okusikeka Ngokulandela Ukuphathwa Kwe-Niacin. NginguJ Ther. 1995; 2: 478-480. Buka okungaqondakali.
  74. I-Litin SC, no-Anderson CF. I-myopathy ehlobene neNicotinic acid: umbiko wamacala amathathu. NginguJ Med. 1989; 86: 481-3. Buka okungaqondakali.
  75. UHexeberg S, uRetterstøl K. [Hypertriglyceridemia - ukuxilonga, ubungozi nokwelashwa]. ITidsskr Noma iLaegeforen. 2004; 124: 2746-9. Buka okungaqondakali.
  76. UGarnett WR. Ukusebenzisana ne-hydroxymethylglutaryl-coenzyme A reductase inhibitors. NginguJ J Health Syst Pharm. 1995; 52: 1639-45. Buka okungaqondakali.
  77. IGadegbeku CA, Dhandayuthapani A, Shrayyef MZ, Egan BM. Imiphumela ye-Hemodynamic ye-nicotinic acid infusion ezifundweni ze-normotensive ne-hypertensive. NginguJ Hypertens. 2003; 16: 67-71. Buka okungaqondakali.
  78. U-O'Brien T, uSilverberg JD, uNguyen TT. Ubuthi obenziwe yiNicotinic acid obuhambisana ne-cytopenia namazinga anciphile e-globulin ebopha i-thyroxine. IMayo Clin Proc. 1992; 67: 465-8. Buka okungaqondakali.
  79. UDaring BD, uLavie CJ, uLohmann TP, uGenton E. Niacin obangelwa i-clotting factor synthesis defence ne-coagulopathy. I-Arch Intern Med. 1992; 152: 861-3. Buka okungaqondakali.
  80. USampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Ukukhishwa okunwetshiwe i-nicotinic acid - i-ejenti yomlomo yenoveli yokulawulwa kwe-phosphate. Int Urol Nephrol. 2006; 38: 171-4. Buka okungaqondakali.
  81. Ng CF, Lee CP, Ho AL, Lee VW. Umphumela we-niacin ekusebenzeni kwe-erectile emadodeni ahlushwa ukungasebenzi kahle kwe-erectile ne-dyslipidemia. J Ucansi Med. 2011; 8: 2883-93. Buka okungaqondakali.
  82. UDuggal JK, Singh M, Attri N, et al. Umphumela wokwelashwa kwe-niacin emiphumeleni yenhliziyo ezigulini ezinesifo semithambo yegazi. UJ Cardiovasc Pharmacol Ther. 2010; 15: 158-66. Buka okungaqondakali.
  83. UCarlson LA, uRosenhamer G. Ukunciphisa ukufa kwabantu eStockholm Ischemic Heart Disease Secondary Prevention Study ngokwelashwa okuhlangene ne-clofibrate ne-nicotinic acid. Acta Med Scand. 1988; 223: 405-18. Buka okungaqondakali.
  84. UBlankenhorn DH, uNessim SA, uJohnson RL, et al. Imiphumela ezuzisayo yokwelashwa okuhlangene kwe-colestipol-niacin ku-atherosclerosis ye-coronary kanye ne-coronary venous bypass grafts. JAMA. 1987; 257: 3233-40. Buka okungaqondakali.
  85. UMack WJ, uSelzer RH, uHodis HN, et al. Ukwehliswa konyaka owodwa nokuhlaziywa kwesikhathi eside kwe-carotid intima-media thickness ehambisana nokwelashwa kwe-colestipol / niacin. Unhlangothi. 1993; 24: 1779-83. Buka okungaqondakali.
  86. IBlankenhorn DH, uSelzer RH, uCrawford DW, et al. Imiphumela ezuzisayo yokwelashwa kwe-colestipol-niacin emthanjeni ojwayelekile we-carotid. Ukwehliswa kweminyaka emibili nemine yobukhulu be-intima-media kukalwa nge-ultrasound. Ukujikeleza. 1993; 88: 20-8. Buka okungaqondakali.
  87. UBrown BG, uZambon A, uPoulin D, et al. Ukusetshenziswa kwe-niacin, statins, kanye nama-resin ezigulini ezine-hyperlipidemia ehlangene. NginguJ Cardiol. 1998; 81 (4A): 52B-59B. Buka okungaqondakali.
  88. UBrown G, u-Albers JJ, uFisher LD, et al. Ukuhlehliswa kwesifo somthambo we-coronary ngenxa yokwelashwa okunciphisayo kwe-lipid emadodeni anezinga eliphakeme le-apolipoprotein B. N Engl J Med. 1990; 323: 1289-98. Buka okungaqondakali.
  89. UBruckert E, uLabreuche J, u-Amarenco P.Ukuhlaziywa kwemeta komphumela we-nicotinic acid yedwa noma ngokuhlanganiswa nemicimbi yenhliziyo nemithambo yegazi. I-atherosclerosis. 2010; 210: 353-61. Buka okungaqondakali.
  90. Izinhloli TD, Grant JM, Stone RE, et al. Ukuqaphela kwakamuva ekwelapheni ama-pellagrins angamakhulu ayisithupha ngokugcizelela okukhethekile ekusetshenzisweni kwe-nicotinic acid ku-prophylaxis. ISouth Med J 1938; 31: 1231.
  91. UMalfait P, uMoren A, uDillon JC, et al. Ukuqhamuka kwe-pellagra okuhlobene nezinguquko kwi-niacin yokudla phakathi kwababaleki baseMozambique eMalawi. I-Int J Epidemiol. 1993; 22: 504-11. Buka okungaqondakali.
  92. UGerber MT, uMondy KE, uYarasheski KE, et al. INiacin kubantu abanegciwane lesandulela ngculaza abane-hyperlipidemia ethola ukwelashwa okunamandla ngezidambisigciwane. I-Clin Infect Dis. 2004; 39: 419-25. Buka okungaqondakali.
  93. Ilungu lePhalamende laseDubé, uWu JW, u-Aberg JA, et al. Ukuphepha nokusebenza kwe-niacin ekhishwe isikhathi eside ekwelapheni i-dyslipidaemia ezigulini ezine-HIV: I-AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006; 11: 1081-9. Buka okungaqondakali.
  94. UBalasubramanyam A, uCoraza I, uSmith EO, et al. Ukuhlanganiswa kwe-niacin ne-fenofibrate nokushintsha kwendlela yokuphila kuthuthukisa i-dyslipidemia ne-hypoadiponectinemia ezigulini ze-HIV ekwelashweni ngezidambisigciwane: imiphumela "yenhliziyo enhle," isilingo esilawulwa ngokungahleliwe. UJ Clin Endocrinol Metab. 2011; 96: 2236-47. Buka okungaqondakali.
  95. U-Elam MB, uHunninghake DB, uDavis KB, et al. Umphumela we-niacin kumazinga we-lipid ne-lipoprotein kanye nokulawulwa kwe-glycemic ezigulini ezinesifo sikashukela kanye nesifo semithambo yegazi: isifundo se-ADMIT: Isivivinyo esingahleliwe. Isifo Se-Arterial Izifo Eziningi Zokungenelela. JAMA. 2000; 284: 1263-70. Buka okungaqondakali.
  96. ICharland SL, iMalone DC. Ukubikezelwa kokuncishiswa komcimbi wenhliziyo nemithambo yegazi kusuka kuzinguquko ze-lipid ezihambisana nokwelashwa okuphezulu kwe-dyslipidemia. I-Curr Med Res Opin. 2010; 26: 365-75. Buka okungaqondakali.
  97. IGoldberg AC. Ukuhlaziywa kwemeta kwezifundo ezilawulwa ngokungahleliwe ngemiphumela ye-niacin ekhishwe isikhathi eside kwabesifazane. NginguJ Cardiol. 2004; 94: 121-4. Buka okungaqondakali.
  98. UMaes BD, uHiele MI, uGeypens BJ, et al. Ukushintshashintsha kwemithi kwesilinganiso sokukhipha isisu esiswini njengoba kulinganiswa yikhabhoni ebhalwe ukuthi i-octanoic acid test breath: ithonya le-erythromycin ne-propantheline. Amathumbu 1994; 35: 333-7. Buka okungaqondakali.
  99. Isitatimende se-FDA kusivivinyo se-AIM-HIGH. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm256841.htm. (Kufinyelelwe ngomhla ka-3 Juni 2011).
  100. Izindaba ze-NIH. I-NIH imisa isilingo somtholampilo ekwelashweni kwe-cholesterol ehlangene. Meyi 26, 2011.http://www.nih.gov/news/health/may2011/nhlbi-26.htm. (Kufinyelelwe ngomhla ka-3 Juni 2011).
  101. Umbhalo we-PL wemininingwane, i-Niacin Plus Statin Yokunciphisa Ingozi Yenhliziyo: Isifundo se-AIM-HIGH. Incwadi KaPhemistri / Incwadi KaPrescriber. Julayi 2011.
  102. UKarthikeyan K, Thappa DM. I-Pellagra nesikhumba. I-Int J Dermatol 2002; 41: 476-81. Buka okungaqondakali.
  103. Hendricks WM. I-Pellagra ne-pellagralike dermatoses: i-etiology, ukuxilongwa okwehlukile, i-dermatopathology, kanye nokwelashwa. USemin Dermatol 1991; 10: 282-92. Buka okungaqondakali.
  104. IBingham LG, iVerma SB. Ukuqhuma kwe-photodistribributed. (Ukuzihlola kwe-American Academy of Dermatology). J I-Acad Dermatol 2005; 52: 929-32.
  105. UNahata MC. I-chloramphenicol. Ku: Evans WE, Schentag JJ, Jusko WJ (eds). I-Pharmacokinetics Esetshenzisiwe: Izimiso Zokuqapha Izidakamizwa Ezelaphayo. 3rd ed., Vancouver, WA: I-Applied Therapeutics, Inc., 1992.
  106. UDing RW, uKolbe K, uMerz B, et al. I-Pharmacokinetics yokusebenzisana kwe-acid nicotinic acid-salicylic acid. I-Clin Pharmacol Ther 1989; 46: 642-7. Buka okungaqondakali.
  107. ILyon VB, iFairley JA. I-pellagra eyenziwe nge-Anticonvulsant. UJ I-Acad Dermatol 2002; 46: 597-9. Buka okungaqondakali.
  108. UKaur S, uGoraya JS, uThami GP, uKanwar AJ. I-Pellagrous dermatitis ebangelwa yi-phenytoin (incwadi). I-Pediatr Derm 2002; 19: 93. Buka okungaqondakali.
  109. UWood B, uRademaker M, u-Oakley A, uWallace J. Pellagra kowesifazane osebenzisa amanye amakhambi. I-Australas J Dermatol 1998; 39: 42-4. Buka okungaqondakali.
  110. I-Bender DA, i-pellagra eyenziwe ngu-Russell-Jones R. Isoniazid yize i-vitamin B6 ingezelela (incwadi). ILancet 1979; 2: 1125-6. Buka okungaqondakali.
  111. UStevens H, Ostlere L, Begent R, et al. I-Pellagra yesibili kuya ku-5-fluorouracil. UBr J Dermatol 1993; 128: 578-80. Buka okungaqondakali.
  112. USwash M, uRoberts AH. I-pellagra efana ne-encephalopathy efana ne-ethionamide ne-cycloserine. I-Tubercle 1972; 53: 132. Buka okungaqondakali.
  113. I-Brooks-Hill RW, uMbhishobhi ME, uVellend H. Pellagra-like encephalopathy efaka uxhaxha lwemithi eminingi yokwelapha ukutheleleka kwamaphaphu ngenxa ye-Mycobacterium avium-intracellulare (incwadi). NginguRev Rev Dis Dis 1985; 131: 476. Buka okungaqondakali.
  114. IBender DA, Earl CJ, Lees AJ. Ukuncipha kukaNiacin ezigulini zaseParkinsonia eziphathwe nge-L-dopa, benserazide ne-carbidopa. I-Clinical Sci 1979; 56: 89-93. . Buka okungaqondakali.
  115. ULudwig GD, i-White DC. I-Pellagra eyenziwe yi-6-mercaptopurine. I-Clin Res 1960; 8: 212.
  116. IStratigos JD, uKatsambas A. Pellagra: isifo esikhona namanje. UBr J Dermatol 1977; 96: 99-106. Buka okungaqondakali.
  117. UJarrett P, Duffill M, Oakley A, Smith A. Pellagra, azathioprine nezifo ezivuthayo zamathumbu. I-Clin Exp Dermatol 1997; 22: 44-5. Buka okungaqondakali.
  118. Imininingwane yomkhiqizo: Niaspan. I-Kos Pharmaceuticals. ECranbury, NJ. 2005. Itholakala ku-www.niaspan.com/professional/content/pdfs/productinfo.pdf. (Kufinyelelwe ngomhla ka-3 Mashi 2006).
  119. ISchwab RA, iBachhuber BH. I-Delirium ne-lactic acidosis ebangelwa yi-ethanol ne-niacin coingestion. Ngingu-J Emerg Med 1991; 9: 363-5. Buka okungaqondakali.
  120. Ito MK. Intuthuko ekuqondeni nasekuphathweni kwe-dyslipidemia: kusetshenziswa izindlela zokwelashwa ezisuselwa ku-niacin. NginguJ J Health-Syst Pharm 2003; 60 (suppl 2): ​​s15-21. Buka okungaqondakali.
  121. Imvubelo P, Witztum JL. I-Lovastatin, i-nicotinic acid ne-rhabdomyolysis (incwadi). U-Ann Int Med 1988; 109: 597-8. Buka okungaqondakali.
  122. Rockwell KA. Ukuxhumana okungaba khona phakathi kwe-niacin ne-transdermal nicotine (incwadi). U-Ann Pharmacother 1993; 27: 1283-4. Buka okungaqondakali.
  123. UGillman MA, Sandyk R.Nicotinic acid ukuntuleka okubangelwa yi-sodium valproate (incwadi). S Afr Med J 1984; 65: 986. Buka okungaqondakali.
  124. Ubaba CM. I-Niacinamide ne-acanthosis nigricans (incwadi). I-Arch Dermatol 1984; 120: 1281. Buka okungaqondakali.
  125. UMorris MC, u-Evans DA, uBianias JL, et al. I-Diac niacin kanye nengozi yesigameko i-Alzheimer's's kanye nokwehla kwengqondo. UJ Neurol Neurosurg Psychiatry 2004; 75: 1093-99. Buka okungaqondakali.
  126. UMcKenney J. Imibono emisha ngokusetshenziswa kwe-niacin ekwelapheni ukuphazamiseka kwe-lipid. I-Arch Intern Med 2004; 164: 697-705. Buka okungaqondakali.
  127. Ukukhulisa i-HDL nokusetshenziswa kwe-Niacin. Incwadi ka-Pharmacist's Letter / Prescriber's 2004; 20: 200504.
  128. IHoskin PJ, iStratford MR, iSaunders MI, et al. Ukuphathwa kwe-nicotinamide phakathi kweshadi: i-pharmacokinetics, ukukhuphuka komthamo, nobuthi bomtholampilo. I-Int J Radiat Oncol Biol Phys 1995; 32: 1111-9. Buka okungaqondakali.
  129. UMiralbell R, uMornex F, uGreiner R, et al. I-radiotherapy esheshayo, i-carbogen, ne-nicotinamide ku-glioblastoma multiforme: umbiko we-European Organisation for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999; 17: 3143-9. Buka okungaqondakali.
  130. Anon. I-Niacinamide Monograph. I-Alt Med Rev 2002; 7: 525-9. Buka okungaqondakali.
  131. ISchwartz ML. I-hyperglycemia ebuyela emuva enamandla ngenxa yokwelashwa kwe-niacin. I-Arch Int Med 1993; 153: 2050-2. Buka okungaqondakali.
  132. UKahn SE, uBeard JC, uSchwartz MW, et al. Ukwandisa amandla we-B-cell secretory njengendlela yokwenza i-islet adaptation to nicotinic acid-indased insulin insulin. Isifo sikashukela 1989; 38: 562-8. Buka okungaqondakali.
  133. URader JI, uCalvert RJ, uHathcock JN. Ubuthi be-hepatic bokulungiswa okungakhanyiswanga nesikhathi sokukhishwa kwe-niacin. NginguJ Med 1992; 92: 77-81. Buka okungaqondakali.
  134. I-Figge HL, i-Figge J, i-Souney PF, et al. I-Nicotinic acid: ukubuyekezwa kokusetshenziswa kwayo kwemitholampilo ekwelapheni ukuphazamiseka kwe-lipid. I-Pharmacotherapy 1988; 8: 287-94. Buka okungaqondakali.
  135. Amabhayi HE, iDujovne CA. Ukusebenzisana kwezidakamizwa ezidambisa lipid. Izidakamizwa Saf 1998; 19: 355-71. Buka okungaqondakali.
  136. UVannucchi H, uMoreno FS. Ukusebenzisana kwe-niacin ne-zinc metabolism ezigulini ezine-pellagra yotshwala. Ngingu-J J Nutriti 1989; 50: 364-9. Buka okungaqondakali.
  137. I-Urberg M, iZemel MB. Ubufakazi be-synergism phakathi kwe-chromium ne-nicotinic acid ekulawuleni ukubekezelelana kwe-glucose kubantu asebekhulile. I-Metabolism 1987; 36: 896-9. Buka okungaqondakali.
  138. UCheung MC, uZhao XQ, uChait A, et al. Izithako ze-antioxidant zivimba ukuphendula kwe-HDL ekwelashweni kwe-simvastatin-niacin ezigulini ezinesifo semithambo yenhliziyo ne-HDL ephansi. I-Arterioscler Thromb Vasc Biol 2001; 21: 1320-6. Buka okungaqondakali.
  139. UChesney CM, u-Elam MB, uHerd JA, et al. Umphumela we-niacin, warfarin, kanye ne-antioxidant therapy kumapharamitha we-coagulation ezigulini ezinesifo semithambo yegazi ku-Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140: 631-6 .. Buka okungaqondakali.
  140. U-Wink J, uGiacoppe G, uKing J. Umphumela we-naicin ephansi kakhulu kwi-high-density lipoprotein ezigulini ezithola ukwelashwa kwe-statin isikhathi eside. Am Heart J 2002; 143: 514-8 .. Buka okungaqondakali.
  141. UWolfe ML, uVartanian SF, uRoss JL, et al. Ukuphepha nokusebenza kwe-Niaspan lapho ingezwa ngokulandelana kwi-statin ekwelapheni i-dyslipidemia. NginguJ J Cardiol 2001; 87: 476-9, A7 .. Buka okungaqondakali.
  142. UBrown BG, uZhao XQ, uChait A, et al. I-Simvastatin ne-niacin, amavithamini e-antioxidant, noma inhlanganisela yokuvimbela isifo se-coronary. N Engl J Med 2001; 345: 1583-93. Buka okungaqondakali.
  143. UCumming RG, Mitchell P, Smith W. Ukudla kanye ne-cataract: iBlue Mountains Eye Study. I-Ophthalmology 2000; 10: 450-6. Buka okungaqondakali.
  144. UKuroki F, u-Iida M, uTominaga M, et al. Isimo samavithamini amaningi kwisifo sikaCrohn. Ukuhlangana nomsebenzi wezifo. I-Dig Dis Sci 1993; 38: 1614-8. Buka okungaqondakali.
  145. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, neCholine. IWashington, DC: National Academy Press, 2000. Itholakala ku: http://books.nap.edu/books/0309065542/html/.
  146. Iwebhusayithi yeAmerican Dietetic Association. Kutholakala ku: www.eatright.org/adap1097.html (Kufinyelelwe ngomhlaka 16 Julayi 1999).
  147. ULal SM, uHewett JE, Petroski GF, et al. Imiphumela ye-nicotinic acid ne-lovastatin ezigulini zokufakelwa kwezinso: isilingo se-crossover esizoba khona, esingahleliwe, esinelebula evulekile. NginguJ J Kidney Dis 1995; 25: 616-22. Buka okungaqondakali.
  148. UGuyton JR, uGoldberg AC, uKreisberg RA, et al. Ukusebenza kokufakwa kwesisindo kanye kanye ebusuku kwe-niacin ekhishwe isikhathi eside iyodwa futhi ngokuhlangana kwe-hypercholesterolemia. NginguJ Cardiol 1998; 82: 737-43. Buka okungaqondakali.
  149. I-Vega GL, iGrundy SM. Izimpendulo ze-Lipoprotein ekwelashweni nge-lovastatin, gemfibrozil, ne-nicotinic acid kwiziguli ze-normolipidemic ezine-hypoalphalipoproteinemia. I-Arch Intern Med 1994; 154: 73-82. Buka okungaqondakali.
  150. I-Vacek JL, i-Dittmeier G, i-Chiarelli T, et al. Ukuqhathaniswa kwe-lovastatin (20 mg) ne-nicotinic acid (1.2 g) nomuthi owodwa wohlobo II hyperlipoproteinemia. NginguJ J Cardiol 1995; 76: 182-4. Buka okungaqondakali.
  151. U-Illingworth DR, uStein EA, uMitchel YB, et al. Imiphumela yokuqhathanisa ye-lovastatin ne-niacin ku-hypercholesterolemia eyinhloko. Ozoqulwa ecaleni. I-Arch Intern Med 1994; 154: 1586-95. Buka okungaqondakali.
  152. UPozzilli P, uBrowne PD, uKolb H. Meta-ukuhlaziywa kokwelapha i-nicotinamide ezigulini ezine-IDDM ezisanda kuqala. Izilingo zeNicotinamide. Ukunakekelwa yisifo sikashukela 1996; 19: 1357-63. Buka okungaqondakali.
  153. UJohansson JO, Egberg N, Asplund-Carlson A, Carlson LA. Ukwelashwa kweNicotinic acid kususa ibhalansi ye-fibrinolytic kahle futhi kunciphise i-plasma fibrinogen emadodeni e-hypertriglyceridaemic. J Cardiovasc Risk 1997; 4: 165-71. Buka okungaqondakali.
  154. URabbani GH, uButler T, uBardhan PK, u-Islam A.Ukuncipha kokulahleka koketshezi kukholera yi-nicotinic acid: isilingo esilawulwa ngokungahleliwe. ILancet 1983; 2: 1439-42. Buka okungaqondakali.
  155. Uhlelo Lukazwelonke Lwemfundo YeCholesterol. Ukwehla Kwecholesterol Esigulini Esinezifo Zenhliziyo Ezihlasela Coronary. 1997. Itholakala ku: http://www.vidyya.com/pdfs/1225cholesterol.pdf. (Kufinyelelwe ngomhla ka-26 Meyi 2016).
  156. UDarvay A, uBasarab T, uMcGregor JM, uRussell-Jones R. Isoniazid wenza i-pellagra naphezu kokungezelelwa kwe-pyridoxine. I-Clin Exp Dermatol 1999; 24: 167-9. Buka okungaqondakali.
  157. Ishii N, Nishihara Y. Pellagra encephalopathy phakathi kweziguli ezinesifo sofuba: ubudlelwane bayo nokwelashwa kwe-isoniazid. UJ Neurol Neurosurg Psychiatry 1985; 48: 628-34. Buka okungaqondakali.
  158. I-American Society of Health-System Pharmacists. Isitatimende Sesikhundla Sokwelashwa se-ASHP ngokusetshenziswa okuphephile kwe-niacin ekuphathweni kwe-dyslipidemias. NginguJ J Health Syst Pharm 1997; 54: 2815-9. Buka okungaqondakali.
  159. ILeighton RF, iGordon NF, i-GS Encane, et al. Ubuhlungu bamazinyo nobama-gingival njengemiphumela emibi yokwelashwa kwe-niacin. Isifuba 1998; 114: 1472-4. Buka okungaqondakali.
  160. UGarg A, uGundundy SM. I-Nicotinic acid njengokwelashwa kwe-dyslipidemia kwisifo sikashukela esingancikile ku-insulin. I-JAMA 1990; 264: 723-6. Buka okungaqondakali.
  161. I-Crouse JR III. Intuthuko entsha ekusetshenzisweni kwe-niacin ekwelapheni i-hyperlipidemia: ukucatshangelwa okusha ekusetshenzisweni kwesidakamizwa esidala. ICoron Artery Dis 1996; 7: 321-6. Buka okungaqondakali.
  162. I-Knopp RH. Amaphrofayli omtholampilo we-niacin ekhanyayo necacile ekhishwe eqhubekayo (i-Niaspan) kanye nomqondo we-physiologic we-dosing yasebusuku. NginguJ J Cardiol 1998; 82: 24U-28U; ingxoxo 39U-41U. Buka okungaqondakali.
  163. UKnopp RH, Alagona P, Davidson M, et al. Ukusebenza okulinganayo kwefomu ekhishwa ngesikhathi ye-niacin (Niaspan) enikezwe kanye-ubusuku kanye ne-niacin ecacile ekuphathweni kwe-hyperlipidemia. I-Metabolism 1998; 47: 1097-104. Buka okungaqondakali.
  164. UMcKenney JM, Proctor JD, Harris S, Chinchili VM. Ukuqhathaniswa kokusebenza kahle kanye nemiphumela enobuthi ye-niacin ekhishwa ngokushesha-ekhishwa ngokushesha ezigulini ze-hypercholesterolemic. I-JAMA 1994; 271: 672-7. Buka okungaqondakali.
  165. IGrey DR, uMorgan T, iChretien SD, iKashyap ML. Ukusebenza nokuphepha kwe-niacin ekhishwa ngokulawulwa kuma-veteran e-dyslipoproteinemic. U-Ann Intern Med 1994; 121: 252-8. Buka okungaqondakali.
  166. ICapuzzi DM, uGuyton JR, uMorgan JM, et al. Ukusebenza nokuphepha kwe-niacin ekhishwe isikhathi eside (i-Niaspan): isifundo sesikhathi eside. NginguJ J Cardiol 1998; 82: 74-81; i-disc. 85U-6U. Buka okungaqondakali.
  167. UJungnickel PW, Maloley PA, Vander Tuin EL, et al. Umphumela wezinhlobo ezimbili zemithi yokwelashwa ngaphambi kokuphathwa kwe-niacin. UJ Gen Intern Med 1997; 12: 591-6. Buka okungaqondakali.
  168. I-Whelan AM, Intengo SO, iFowler SF, iHainer BL. Umphumela we-aspirin ekuphenduleni kwe-niacin okubangelwa ukusikwa. UJ Fam Pract 1992; 34: 165-8. Buka okungaqondakali.
  169. IGibbons LW, uGonzalez V, uGordon N, uGrundy S. Ukusabalala kwemiphumela emibi nge-nicotinic acid ejwayelekile neqhubekayo. NginguJ Med 1995; 99: 378-85. Buka okungaqondakali.
  170. IPark YK, iSempos CT, iBarton CN, et al. Ukusebenza kokuqiniswa kokudla e-United States: icala le-pellagra. NginguJ J Health Public 2000; 90: 727-38. Buka okungaqondakali.
  171. UZhao XQ, uBrown BG, uHillger L, et al. Imiphumela yokwelashwa okunciphisayo kwe-lipid emithanjeni ye-coronary yezihloko ze-asymptomatic ezine-apolipoprotein ephakemeI-circulation 1993; 88: 2744-53. Buka okungaqondakali.
  172. ICanner PL, iBergge KG, uWenger NK, et al. Ukufa kweminyaka eyishumi nanhlanu ezigulini zeCoronary Drug Project: inzuzo yesikhathi eside nge-niacin. UJ Am Coll Cardiol 1986; 8: 1245-55. Buka okungaqondakali.
  173. UGuyton JR, ovutha MA, uHagar J, et al. I-niacin ekhishwe enwetshiwe vs gemfibrozil yokwelashwa kwamazinga aphansi we-high-density lipoprotein cholesterol. Iqembu le-Niaspan-Gemfibrozil Study. I-Arch Intern Med 2000; 160: 1177-84. Buka okungaqondakali.
  174. UZema MJ. I-Gemfibrozil, i-nicotinic acid kanye nokwelashwa kokuhlanganiswa kweziguli ezine-hypoalphalipoproteinemia ehlukanisiwe: isifundo esingahleliwe, esinelebuli evulekile, isifundo se-crossover. UJ Am Coll Cardiol 2000; 35: 640-6. Buka okungaqondakali.
  175. IKnodel LC, uTalbert RL. Imiphumela emibi yezidakamizwa ze-hypolipidaemic. IMed Toxicol 1987; 2: 10-32. Buka okungaqondakali.
  176. I-Yates AA, iSchlicker SA, iSuitor CW. Ukufakwa kwereferensi yokudla: Isisekelo esisha sezincomo ze-calcium nezakhi ezihlobene, amavithamini B, ne-choline. J Am Ukudla Assoc 1998; 98: 699-706. Buka okungaqondakali.
  177. I-Shils ME, u-Olson JA, uShike M, uRoss AC, ama-eds. Ukondleka Kwamanje Ezempilo Nezifo. Umhlaka 9. IBaltimore, MD: Williams & Wilkins, 1999.
  178. UReimund E. Ukulala okubangelwa ukulala okubangelwa ukulala: ukusekelwa okuqhubekayo kokuncipha kwe-nicotinic acid ekunciphiseni ubuthongo. I-Med Hypotheses 1991; 36: 371-3. Buka okungaqondakali.
  179. U-Ioannides-Demos LL, uChristophidis N, et al. Ukulinganisa imiphumela yokuhlangana komtholampilo phakathi kwejusi lamagilebhisi kanye ne-cyclosporine kanye nokugxila kwe-metabolite ezigulini ezinezifo ezizimele. UJ Rheumatol 1997; 24: 49-54. Buka okungaqondakali.
  180. UHardman JG, uLimbird LL, uMolinoff PB, ama-eds. UGoodman noGillman’s The Pharmacological Basis of Therapeutics, umhla ka-9. ENew York, NY: McGraw-Hill, 1996.
  181. UGarg R, uMalinow MR, uPettinger M, et al. Ukwelashwa kwe-Niacin kwandisa amazinga e-plasma homocysteine. Nginhliziyo J 1999; 138: 1082-7. Buka okungaqondakali.
  182. UGruenwald J, Brendler T, Jaenicke C. PDR weMithi Yemithi. 1st ed. IMontvale, NJ: I-Medical Economics Company, Inc., ngo-1998.
  183. UMcEvoy GK, umhleli. Imininingwane Yezidakamizwa ze-AHFS. I-Bethesda, MD: I-American Society of Health-System Pharmacists, ngo-1998.
Kugcine ukubuyekezwa - 10/16/2020

Izincwadi Ezintsha

Okufanele Ukwazi Ngezinhlungu Ezihlangene
Impilo

Okufanele Ukwazi Ngezinhlungu Ezihlangene

Amalunga ayizitho zomzimba wakho lapho kuhlangana khona amathambo akho. Amalunga avumela amathambo wamathambo akho ukuba ahambe. Amalungu afaka:emahlombeokhalweniIzindololwaneamadoloUbuhlungu obuhlang...
Kungani i-MRI Isetshenziselwa Ukuthola I-Multiple Sclerosis
Impilo

Kungani i-MRI Isetshenziselwa Ukuthola I-Multiple Sclerosis

I-Multiple clero i (M ) yi imo lapho ama o ha omzimba ahla ela khona i embozo okuvikela (myelin) e izungeze izinzwa ze i timu yezinzwa emaphakathi (CN ). Akunakho ukuhlolwa okukodwa okucacile okungath...